Entrada Therapeutics has appointed Nathan Dowden to serve as its chief operating officer. He joins Boston-based Entrada from Rubius Therapeutics, where he was senior vice president of strategy and corporate development. Entrada is developing drugs that that use cell-penetrating peptides to bring a therapy into a cell. Last year, the biotech raised $59 million in Series A financing.
Sponsored · Video
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
